2型糖尿病长期血糖变异性与血管并发症:FIELD研究的事后分析
该研究为FIELD试验的事后分析,评估2型糖尿病患者长期血糖变异性与血管并发症的关联。结果显示,糖化血红蛋白和空腹血糖的变异系数与微血管并发症、心血管疾病、总死亡等风险增加相关。结论认为长期血糖变异性与2型糖尿病血管结局风险增加相关。
要点
- 糖化血红蛋白变异系数与微血管并发症风险增加相关(HR 1.02)。
- 空腹血糖变异系数与微血管并发症风险增加相关(HR 1.01)。
- 糖化血红蛋白和空腹血糖变异系数均与总死亡风险增加相关(HR 1.04和HR 1.01)。
核心结论
- 长期血糖变异性与2型糖尿病血管结局风险增加相关。
研究设计与样本
- FIELD试验的事后分析,计算糖化血红蛋白和空腹血糖的标准差及变异系数作为血糖变异性指标。
- 采用卡方检验和方差分析比较研究中变异性四分位组的基线变量。
- 采用界标逻辑回归和Cox比例风险回归分析基线至2年血糖变异性与后续血管及死亡结局的前瞻性关联。
主要发现
- 与研究中血糖变异性较高相关的基线因素包括较年轻年龄、男性、较长糖尿病病程和较高药物治疗使用。
- 糖化血红蛋白变异系数与微血管并发症风险增加相关(HR 1.02,95%CI 1.01-1.03,P<0.01);空腹血糖变异系数与微血管并发症风险增加相关(HR 1.01,95%CI 1.00-1.01,P<0.001)。
- 糖化血红蛋白变异系数与心血管疾病风险增加相关(HR 1.02,95%CI 1.00-1.04,P<0.05);空腹血糖变异系数与心血管疾病风险增加相关(HR 1.01,95%CI 1.00-1.02,P<0.05)。
- 糖化血红蛋白变异系数与卒中风险增加相关(HR 1.03,95%CI 1.01-1.06,P<0.01);空腹血糖变异系数与冠状动脉事件风险增加相关(HR 1.01,95%CI 1.00-1.02,P<0.05)。
- 糖化血红蛋白变异系数与总死亡风险增加相关(HR 1.04,95%CI 1.02-1.06,P<0.001);空腹血糖变异系数与总死亡风险增加相关(HR 1.01,95%CI 1.01-1.02,P<0.001);糖化血红蛋白变异系数与非心血管死亡风险增加相关(HR 1.05,95%CI 1.03-1.07,P<0.001);空腹血糖变异系数与非心血管死亡风险增加相关(HR 1.02,95%CI 1.01-1.03,P<0.001);糖化血红蛋白变异系数与冠状动脉死亡风险增加相关(HR 1.04,95%CI 1.01-1.07,P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate whether long-term glycemic variability (GV) is associated with vascular complication development in type 2 diabetes. METHODS: In a post hoc FIELD trial analysis, GV was calculated as the standard deviation and coefficient of variation (CV) of glycated hemoglobin A1c (HbA1c) and fasting plasma glucose. Baseline variables were compared across quartiles of on-study variability by chi square and ANOVA. Prospective associations between baseline to 2-year GV and subsequent vascular and mortality outcomes were analyzed using landmark logistic and Cox proportional hazards regression. RESULTS: Baseline factors associated with higher on-study GV included younger age, male gender, longer diabetes duration, and higher pharmacological therapies usage. Both HbA1c and fasting glucose CV were associated with increased risk of microvascular complications (HR 1.02 [95% CI, 1.01-1.03] P < 0.01; and HR 1.01 [95% CI, 1.00-1.01] P < 0.001, respectively). HbA1c and fasting glucose CV were associated with increased cardiovascular disease (HR 1.02 [95% CI, 1.00-1.04]; and HR 1.01 [95% CI, 1.00-1.02], both P < 0.05). HbA1c CV associated with increased stroke (HR 1.03 [95% CI, 1.01-1.06) P < 0.01). Glucose CV associated with increased coronary events (HR 1.01 [95% CI, 1.00-1.02] P < 0.05). Both HbA1c and glucose CV associated with increased total mortality (HR 1.04 [95% CI, 1.02-1.06]; and HR 1.01 [95% CI, 1.01-1.02], both P < 0.001) and noncardiovascular mortality (HR 1.05 [95% CI, (1.03-1.07]; and HR 1.02 [95% CI, 1.01-1.03], both P < 0.001). HbA1c CV associated with coronary mortality (HR 1.04 [95% CI, 1.01-1.07] P < 0.05). CONCLUSIONS: Long-term GV was associated with increased risk of vascular outcomes in type 2 diabetes.
引用
- Scott ES, Januszewski AS, O'Connell R, et al. Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study. J Clin Endocrinol Metab. 2020. PMID: 32766757. doi:10.1210/clinem/dgaa361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。